Meinhard Kieser

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8331135/publications.pdf

Version: 2024-02-01

163	4,294	172457	155660
papers	citations	29 h-index	55 g-index

175	175	175	5116
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A note on the shape of sample size functions of optimal adaptive two-stage designs. Communications in Statistics - Theory and Methods, 2022, 51, 1911-1918.	1.0	1
2	An adaptive design for early clinical development including interim decision for singleâ€arm trial with external controls or randomized trial. Pharmaceutical Statistics, 2022, 21, 625-640.	1.3	5
3	Using independent crossâ€sectional survey data to predict postâ€migration health trajectories among refugees by estimating transition probabilities and their variances. Biometrical Journal, 2022, 64, 964-983.	1.0	5
4	Optimization of adaptive designs with respect to a performance score. Biometrical Journal, 2022, 64, 989-1006.	1.0	1
5	A comparison of methods for enriching network metaâ€analyses in the absence of individual patient data. Research Synthesis Methods, 2022, , .	8.7	0
6	Full Reperfusion Without Functional Independence After Mechanical Thrombectomy in the Anterior Circulation. Clinical Neuroradiology, 2022, 32, 987-995.	1.9	11
7	Effect of Early vs Standard Approach to Tracheostomy on Functional Outcome at 6 Months Among Patients With Severe Stroke Receiving Mechanical Ventilation. JAMA - Journal of the American Medical Association, 2022, 327, 1899.	7.4	42
8	Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases.. Journal of Clinical Oncology, 2022, 40, LBA3507-LBA3507.	1.6	18
9	Utilizing radar graphs in the visualization of simulation and estimation results in network metaâ€analysis. Research Synthesis Methods, 2021, 12, 96-105.	8.7	9
10	Optimal Designs for Multi-Arm Phase II/III Drug Development Programs. Statistics in Biopharmaceutical Research, 2021, 13, 71-81.	0.8	2
11	The adoptr Package: Adaptive Optimal Designs for Clinical Trials in R. Journal of Statistical Software, 2021, 98, .	3.7	5
12	Individualized blood pressure management during endovascular treatment of acute ischemic stroke under procedural sedation (INDIVIDUATE) â€“ An explorative randomized controlled trial. European Stroke Journal, 2021, 6, 276-282.	5.5	10
13	Optimal planning of adaptive twoâ€stage designs. Statistics in Medicine, 2021, 40, 3196-3213.	1.6	6
14	Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?. Journal of Neuro-Oncology, 2021, 152, 483-490.	2.9	13
15	Improving sample size recalculation in adaptive clinical trials by resampling. Pharmaceutical Statistics, 2021, 20, 1035-1050.	1.3	0
16	FASTER and SCOTT&EVA trainings for adults with high-functioning autism spectrum disorder (ASD): study protocol for a randomized controlled trial. Trials, 2021, 22, 261.	1.6	4
17	Predictors for Failure of Early Neurological Improvement After Successful Thrombectomy in the Anterior Circulation. Stroke, 2021, 52, 1291-1298.	2.0	26
18	Categories, components, and techniques in a modular construction of basket trials for application and further research. Biometrical Journal, 2021, 63, 1159-1184.	1.0	8

#	Article	IF	Citations
19	Hemodynamic Status During Endovascular Stroke Treatment: Association of Blood Pressure with Functional Outcome. Neurocritical Care, 2021, 35, 825-834.	2.4	10
20	Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study. BMC Cancer, 2021, 21, 812.	2.6	9
21	Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 5546-5556.	7.0	22
22	Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. Trials, 2021, 22, 765.	1.6	2
23	Emergency intubation during thrombectomy for acute ischemic stroke in patients under primary procedural sedation. Neurological Research and Practice, 2021, 3, 27.	2.0	1
24	Interventions to reduce the incidence of surgical site infection in colorectal resections: systematic review with multicomponent network meta-analysis (INTRISSI): study protocol. BMJ Open, 2021, 11, e057226.	1.9	1
25	Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapyâ€"GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study. Radiation Oncology, 2021, 16, 240.	2.7	4
26	Optimal adaptive single-arm phase II trials under quantified uncertainty. Journal of Biopharmaceutical Statistics, 2020, 30, 89-103.	0.8	4
27	Sample size calculation and blinded recalculation for analysis of covariance models with multiple random covariates. Journal of Biopharmaceutical Statistics, 2020, 30, 143-159.	0.8	3
28	Integrated evaluation of targeted and nonâ€targeted therapies in a network metaâ€analysis. Biometrical Journal, 2020, 62, 777-789.	1.0	2
29	Adjustment for exploratory cutâ€off selection in randomized clinical trials with survival endpoint. Biometrical Journal, 2020, 62, 627-642.	1.0	1
30	Primary Open Versus Closed Implantation Strategy for Totally Implantable Venous Access Ports. Annals of Surgery, 2020, 272, 950-960.	4.2	15
31	Comments on â€œAdaptive sample size modification in clinical trials: Start small then ask for more?â€. Statistics in Medicine, 2020, 39, 97-98.	1.6	0
32	Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study. BMC Cancer, 2020, 20, 947.	2.6	12
33	Comparison of Methods for Estimating Therapy Effects by Indirect Comparisons: A Simulation Study. Medical Decision Making, 2020, 40, 644-654.	2.4	5
34	Optimal decisionâ€making in oncology development programs based on probability of success for phase III utilizing phase II / III data on response and overall survival. Pharmaceutical Statistics, 2020, 19, 861-881.	1.3	0
35	Optimal designs for phase II/III drug development programs including methods for discounting of phase II results. BMC Medical Research Methodology, 2020, 20, 253.	3.1	4
36	Study protocol of the multi-centre, randomised controlled trial of the Frankfurt Early Intervention Programme A-FFIP versus early intervention as usual for toddlers and preschool children with Autism Spectrum Disorder (A-FFIP study). Trials, 2020, 21, 217.	1.6	5

#	Article	IF	Citations
37	A comparison of Bayesian and frequentist methods in randomâ€effects network metaâ€analysis of binary data. Research Synthesis Methods, 2020, 11, 363-378.	8.7	31
38	Why do you need a biostatistician?. BMC Medical Research Methodology, 2020, 20, 23.	3.1	16
39	Incorporating historical twoâ€arm data in clinical trials with binary outcome: A practical approach. Pharmaceutical Statistics, 2020, 19, 662-678.	1.3	3
40	A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation. Statistics in Medicine, 2020, 39, 2067-2100.	1.6	7
41	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. Trials, 2020, 21, 352.	1.6	7
42	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomized controlled trials.. Journal of Clinical Oncology, 2020, 38, 4533-4533.	1.6	1
43	Adaptive propensity score procedure improves matching in prospective observational trials. BMC Medical Research Methodology, 2019, 19, 150.	3.1	1
44	A variational approach to optimal twoâ€stage designs. Statistics in Medicine, 2019, 38, 4159-4171.	1.6	16
45	Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial. PLoS ONE, 2019, 14, e0222993.	2.5	16
46	Psychometric validation of the Breast Cancer Treatment Outcome Scale (BCTOS-12): a prospective cohort study. Archives of Gynecology and Obstetrics, 2019, 300, 1679-1686.	1.7	5
47	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. European Journal of Cancer, 2019, 123, 101-111.	2.8	10
48	Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study. Radiation Oncology, 2019, 14, 179.	2.7	11
49	Refining scores based on patient reported outcomes â€“ statistical and medical perspectives. BMC Medical Research Methodology, 2019, 19, 167.	3.1	30
50	Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 open, national, multi-center phase II trial. Trials, 2019, 20, 544.	1.6	9
51	Association of General Anesthesia vs Procedural Sedation With Functional Outcome Among Patients With Acute Ischemic Stroke Undergoing Thrombectomy. JAMA - Journal of the American Medical Association, 2019, 322, 1283.	7.4	140
52	The KEEP SIMPLEST Study: Improving In-House Delays and Periinterventional Management in Stroke Thrombectomyâ€"A Matched Pair Analysis. Neurocritical Care, 2019, 31, 46-55.	2.4	12
53	Simulation and dataâ€generation for randomâ€effects network metaâ€analysis of binary outcome. Statistics in Medicine, 2019, 38, 3288-3303.	1.6	7
54	COMPARE Family (Children of Mentally Ill Parents at Risk Evaluation): A Study Protocol for a Preventive Intervention for Children of Mentally Ill Parents (Triple P, Evidence-Based Program That) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Multicenter RCTâ€"Part II. Frontiers in Psychiatry, 2019, 10, 54.	2.6	19

#	Article	IF	Citations
55	Children of Mentally Ill Parents at Risk Evaluation (COMPARE): Design and Methods of a Randomized Controlled Multicenter Studyâ€"Part I. Frontiers in Psychiatry, 2019, 10, 128.	2.6	23
56	Optimal sample size allocation and go/noâ€go decision rules for phase II/III programs where several phase III trials are performed. Biometrical Journal, 2019, 61, 357-378.	1.0	3
57	Endovascular stroke treatmentâ€™s impact on malignant type of edema (ESTIMATE). Journal of Neurology, 2019, 266, 223-231.	3.6	23
58	What makes a biostatistician?. Statistics in Medicine, 2019, 38, 695-701.	1.6	14
59	Robotic Radiosurgery for Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence (CYBER-SPACE)â€"A Single-Center Prospective Randomized Trial. Neurosurgery, 2019, 84, 253-260.	1.1	8
60	Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints. Clinical Research in Cardiology, 2018, 107, 437-443.	3.3	17
61	A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs. European Journal of Clinical Pharmacology, 2018, 74, 549-559.	1.9	7
62	Testâ€compatible confidence intervals for adaptive twoâ€stage singleâ€arm designs with binary endpoint. Biometrical Journal, 2018, 60, 196-206.	1.0	6
63	A weighted combined effect measure for the analysis of a composite timeâ€toâ€firstâ€event endpoint with components of different clinical relevance. Statistics in Medicine, 2018, 37, 749-767.	1.6	21
64	Association of Blood Pressure With Short- and Long-Term Functional Outcome After Stroke Thrombectomy. Stroke, 2018, 49, 1451-1456.	2.0	56
65	Bright light therapy versus physical exercise to prevent co-morbid depression and obesity in adolescents and young adults with attention-deficit / hyperactivity disorder: study protocol for a randomized controlled trial. Trials, 2018, 19, 140.	1.6	26
66	Optimal planning of phase II/III programs for clinical trials with multiple endpoints. Pharmaceutical Statistics, 2018, 17, 437-457.	1.3	3
67	Evaluation of Stereotactic Radiotherapy of the Resection Cavity After Surgery of Brain Metastases Compared to Postoperative Whole-Brain Radiotherapy (ESTRON)â€"A Single-Center Prospective Randomized Trial. Neurosurgery, 2018, 83, 566-573.	1.1	8
68	Multiple prevalent fractures in relation to macroscopic bone architecture in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 114-120.	0.7	15
69	Timing of the interim analysis in adaptive enrichment designs. Journal of Biopharmaceutical Statistics, 2018, 28, 622-632.	0.8	2
70	Hypothesis testing in Bayesian network meta-analysis. BMC Medical Research Methodology, 2018, 18, 128.	3.1	14
71	Whole brain radiation therapy alone versus radiosurgery for patients with 1â€"10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial. Trials, 2018, 19, 388.	1.6	25
72	Use of the wearable cardioverter-defibrillator (WCD) and WCD-based remote rhythm monitoring in a real-life patient cohort. Heart and Vessels, 2018, 33, 1390-1402.	1.2	13

#	Article	IF	Citations
73	Prognostic relevance of elevated pulmonary arterial pressure assessed non-invasively: Analysis in a large patient cohort with invasive measurements in near temporal proximity. PLoS ONE, 2018, 13, e0191206.	2.5	3
74	Conduct disorder in adolescent females: current state of research and study design of the FemNAT-CD consortium. European Child and Adolescent Psychiatry, 2018, 27, 1077-1093.	4.7	55
75	Two-stage phase II oncology designs using short-term endpoints for early stopping. Statistical Methods in Medical Research, 2017, 26, 1671-1683.	1.5	15
76	Blinded sample size recalculation in clinical trials with binary composite endpoints. Journal of Biopharmaceutical Statistics, 2017, 27, 705-715.	0.8	8
77	Simulation-based adjustment after exploratory biomarker subgroup selection in phase II. Statistics in Medicine, 2017, 36, 2378-2390.	1.6	3
78	Cryoballoon vs. open irrigated radiofrequency ablation for paroxysmal atrial fibrillation: long-term FreezeAF outcomes. BMC Cardiovascular Disorders, 2017, 17, 135.	1.7	19
79	The Impact of Conscious Sedation versus General Anesthesia for Stroke Thrombectomy on the Predictive Value of Collateral Status: A Post Hoc Analysis of the SIESTA Trial. American Journal of Neuroradiology, 2017, 38, 1580-1585.	2.4	10
80	Optimal Interim Decision Rules Based on a Binary Surrogate Outcome for Adaptive Biomarker-Based Trials in Oncology. Statistics in Biopharmaceutical Research, 2017, 9, 321-332.	0.8	3
81	Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial. Lancet, The, 2017, 390, 1027-1037.	13.7	124
82	Blinded sample size recalculation in clinical trials incorporating historical data. Contemporary Clinical Trials, 2017, 63, 2-7.	1.8	2
83	Point estimation in adaptive enrichment designs. Statistics in Medicine, 2017, 36, 3935-3947.	1.6	13
84	Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2017, 99, 912-920.	0.8	13
85	Bayesian network metaâ€analysis for cluster randomized trials with binary outcomes. Research Synthesis Methods, 2017, 8, 236-250.	8.7	15
86	Community Violence Exposure and Conduct Problems in Children and Adolescents with Conduct Disorder and Healthy Controls. Frontiers in Behavioral Neuroscience, 2017, 11, 219.	2.0	29
87	Choice of futility boundaries for group sequential designs with two endpoints. BMC Medical Research Methodology, 2017, 17, 119.	3.1	19
88	A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. BMC Cancer, 2017, 17, 576.	2.6	36
89	Clinical Trial Examples with (Composite) Time-to-Event Endpoints. Springer Series in Pharmaceutical Statistics, 2017, , 225-248.	0.0	0
90	Weighted Composite Time-to-Event Endpoint. Springer Series in Pharmaceutical Statistics, 2017, , 151-155.	0.0	0

#	Article	IF	Citations
91	Statistical methods for the analysis of adverse event data. Pharmaceutical Statistics, 2016, 15, 290-291.	1.3	2
92	Comments on â€˜Hypothesis testing for twoâ€stage designs with over or under enrollmentâ€™. Statistics in Medicine, 2016, 35, 1558-1559.	1.6	0
93	Groupâ€based cognitive behavioural psychotherapy for children and adolescents with <scp>ASD</scp>: the randomized, multicentre, controlled <scp>SOSTA</scp> â€“ net trial. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2016, 57, 596-605.	5.2	51
94	Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset. Data in Brief, 2016, 7, 654-657.	1.0	2
95	Early tracheostomy in ventilated stroke patients: Study protocol of the international multicentre randomized trial SETPOINT2 (Stroke-related Early Tracheostomy vs. Prolonged Orotracheal) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T		
96	A method for using real world data in breast cancer modeling. Journal of Biomedical Informatics, 2016, 60, 385-394.	4.3	20
97	Adverse event development in clinical oncology trials. Lancet Oncology, The, 2016, 17, e263-e264.	10.7	3
98	Assessing additional benefit in noninferiority trials. Biometrical Journal, 2016, 58, 154-169.	1.0	5
99	Effect of Conscious Sedation vs General Anesthesia on Early Neurological Improvement Among Patients With Ischemic Stroke Undergoing Endovascular Thrombectomy. JAMA - Journal of the American Medical Association, 2016, 316, 1986.	7.4	402
100	Utilityâ€based optimization of phase II/III programs. Statistics in Medicine, 2016, 35, 305-316.	1.6	15
101	The SETscore to Predict Tracheostomy Need in Cerebrovascular Neurocritical Care Patients. Neurocritical Care, 2016, 25, 94-104.	2.4	53
102	Performance of Biomarker-Based Subgroup Selection Rules in Adaptive Enrichment Designs. Statistics in Biosciences, 2016, 8, 8-27.	1.2	3
103	Sample size planning for phase II trials based on success probabilities for phase III. Pharmaceutical Statistics, 2015, 14, 515-524.	1.3	18
104	Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials. Statistics in Medicine, 2015, 34, 2128-2137.	1.6	15
105	Education to a Healthy Lifestyle Improves Symptoms and Cardiovascular Risk Factors - AsuRiesgo Study. Arquivos Brasileiros De Cardiologia, 2015, 104, 347-55.	0.8	14
106	Identification of physicians with unusual performance in screening colonoscopy databases: a Bayesian approach. Gastrointestinal Endoscopy, 2015, 81, 646-654.e1.	1.0	6
107	Efficacy and Safety of Triple Combination Therapy With Artesunate-Amodiaquineâ€“Methylene Blue for Falciparum Malaria in Children: A Randomized Controlled Trial in Burkina Faso. Journal of Infectious Diseases, 2015, 211, 689-697.	4.0	51
108	Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas. Journal of Biopharmaceutical Statistics, 2015, 25, 1285-1311.	0.8	9

#	Article	IF	Citations
109	Performance of Adaptive Designs for Single-Armed Phase II Oncology Trials. Journal of Biopharmaceutical Statistics, 2015, 25, 602-615.	0.8	2
110	Optimal Decision Rules for Biomarker-Based Subgroup Selection for a Targeted Therapy in Oncology. International Journal of Molecular Sciences, 2015, 16, 10354-10375.	4.1	8
111	Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial. BMC Cancer, 2015, 15, 192.	2.6	10
112	Sedation vs. Intubation for Endovascular Stroke TreAtment (SIESTA) â€“ A Randomized Monocentric Trial. International Journal of Stroke, 2015, 10, 969-978.	5.9	80
113	Twoâ€stage designs for crossâ€over bioequivalence trials. Statistics in Medicine, 2015, 34, 2403-2416.	1.6	24
114	Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. Journal of Radiation Research, 2015, 56, 742-749.	1.6	20
115	Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation. Circulation, 2015, 132, 1311-1319.	1.6	234
116	Predictors of Residual Tumor in Breast-Conserving Therapy. Annals of Surgical Oncology, 2015, 22, 451-458.	1.5	12
117	Opportunities and challenges of clinical trials in cardiology using composite primary endpoints. World Journal of Cardiology, 2015, 7, 1.	1.5	18
118	Opportunities and challenges of combined effect measures based on prioritized outcomes. Statistics in Medicine, 2014, 33, 1104-1120.	1.6	44
119	Decision Rules for Subgroup Selection Based on a Predictive Biomarker. Journal of Biopharmaceutical Statistics, 2014, 24, 188-202.	0.8	23
120	Easily applicable multiple testing procedures to improve the interpretation of clinical trials with composite endpoints. International Journal of Cardiology, 2014, 175, 126-132.	1.7	9
121	Antibiotic sutures against surgical site infectionsâ€“Authors' reply. Lancet, The, 2014, 384, 1425-1426.	13.7	2
122	Effectiveness of triclosan-coated PDS Plus versus uncoated PDS II sutures for prevention of surgical site infection after abdominal wall closure: the randomised controlled PROUD trial. Lancet, The, 2014, 384, 142-152.	13.7	153
123	Blinded sample size reâ€estimation in crossover bioequivalence trials. Pharmaceutical Statistics, 2014, 13, 157-162.	1.3	19
124	Statistical Methods for the Assessment of Clinical Relevance. , 2014, , 195-207.		1
125	Assessment of statistical significance and clinical relevance. Statistics in Medicine, 2013, 32, 1707-1719.	1.6	44
126	Sample Size Calculation and Blinded Sample Size Recalculation in Clinical Trials Where the Treatment Effect is Measured by the Relative Risk. Communications in Statistics Part B: Simulation and Computation, 2013, 42, 1643-1653.	1.2	2

#	Article	IF	Citations
127	Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations. Therapeutic Innovation and Regulatory Science, 2013, 47, 460-467.	1.6	5
128	Optimal adaptive twoâ€stage designs for phase II cancer clinical trials. Biometrical Journal, 2013, 55, 955-968.	1.0	23
129	Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC Cancer, 2012, 12, 137.	2.6	46
130	Quality of reporting of clinical non-inferiority and equivalence randomised trials - update and extension. Trials, 2012, 13, 214.	1.6	40
131	To test or not to test: Preliminary assessment of normality when comparing two independent samples. BMC Medical Research Methodology, 2012, 12, 81.	3.1	151
132	Adaptive designs for singleâ€arm phase II trials in oncology. Pharmaceutical Statistics, 2012, 11, 241-249.	1.3	17
133	Considerations on what constitutes a â€˜qualified statisticianâ€™ in regulatory guidelines. Statistics in Medicine, 2012, 31, 1303-1305.	1.6	9
134	A general approach for sample size calculation for the threeâ€arm â€˜gold standardâ€™ nonâ€inferiority design. Statistics in Medicine, 2012, 31, 3579-3596.	1.6	28
135	Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials. Biometrics, 2012, 68, 886-892.	1.4	17
136	A closer look at the effect of preliminary goodnessâ€ofâ€fit testing for normality for the oneâ€sample tâ€test. British Journal of Mathematical and Statistical Psychology, 2011, 64, 410-426.	1.4	21
137	Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 Study. BMC Cancer, 2011, 11, 41.	2.6	26
138	Planning and analysis of three-arm non-inferiority trials with binary endpoints. Statistics in Medicine, 2011, 30, 300-300.	1.6	0
139	Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis. Pharmaceutical Statistics, 2011, 10, 8-13.	1.3	27
140	Blinded sample size recalculation in multicentre trials with normally distributed outcome. Biometrical Journal, 2010, 52, 377-399.	1.0	5
141	ChroPac-Trial: Duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for chronic pancreatitis. Trial protocol of a randomised controlled multicentre trial. Trials, 2010, 11, 47.	1.6	28
142	Blinded assessment of treatment effects utilizing information about the randomization block length. Statistics in Medicine, 2009, 28, 1690-1706.	1.6	8
143	Planning and analysis of three-arm non-inferiority trials with binary endpoints. Statistics in Medicine, 2007, 26, 253-273.	1.6	49
144	Sample Size Recalculation in Internal Pilot Study Designs: A Review. Biometrical Journal, 2006, 48, 537-555.	1.0	153

#	Article	IF	Citations
145	Monitoring Continuous Long-Term Outcomes in Adaptive Designs. Communications in Statistics Part B: Simulation and Computation, 2005, 34, 321-341.	1.2	1
146	Assessment of clinical relevance by considering point estimates and associated confidence intervals. Pharmaceutical Statistics, 2005, 4, 101-107.	1.3	31
147	Power and sample size determination when assessing the clinical relevance of trial results by â€˜responder analysesâ€™. Statistics in Medicine, 2004, 23, 3287-3305.	1.6	27
148	Sample size recalculation for binary data in internal pilot study designs. Pharmaceutical Statistics, 2004, 3, 269-279.	1.3	42
149	A Comparison of Procedures for Adaptive Choice of Location Tests in Flexible Two-Stage Designs. Biometrical Journal, 2003, 45, 292-310.	1.0	12
150	Blinded sample size reassessment in nonâ€inferiority and equivalence trials. Statistics in Medicine, 2003, 22, 995-1007.	1.6	41
151	Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Statistics in Medicine, 2003, 22, 3571-3581.	1.6	108
152	On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation. Statistics in Medicine, 2002, 21, 165-176.	1.6	57
153	A comparison of methods for adaptive sample size adjustment. Statistics in Medicine, 2001, 20, 3861-3873.	1.6	81
154	Re-calculating the sample size in internal pilot study designs with control of the type I error rate. , 2000, 19, 901-911.		108
155	Sample size determination for proving equivalence based on the ratio of two means for normally distributed data. , 1999, 18, 93-105.		77
156	Combining different phases in the development of medical treatments within a single trial. , 1999, 18, 1833-1848.		240
157	Inference on Multiple Endpoints in Clinical Trials with Adaptive Interim Analyses. Biometrical Journal, 1999, 41, 261-277.	1.0	112
158	Configural Frequency Analysis (CFA) Revisited â€” a New Look at an Old Approach. Biometrical Journal, 1999, 41, 967-983.	1.0	17
159	Diagnostic instruments for autism spectrum disorder (ASD). The Cochrane Library, 0, , .	2.8	0
160	Preoperative chemoradiotherapy versus chemotherapy for adenocarcinoma of the esophagus and esophagogastric junction (AEG): systematic review with individual participant data (IPD) network meta-analysis (NMA). The Cochrane Library, 0, , .	2.8	1
161	Monotonicity conditions for avoiding counterintuitive decisions in basket trials. Biometrical Journal, 0, , .	1.0	1
162	Optimal unplanned design modification in adaptive twoâ€stage trials. Pharmaceutical Statistics, 0, , .	1.3	0

#	Article	IF	Citations
163	Two-stage designs with small sample sizes. Journal of Biopharmaceutical Statistics, 0, , 1-7.	0.8	0